Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age40-90
SponsorGuangxi Medical University
About this trial
This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal ultrasound and postoperative digital pathological whole slide images. The study is designed to achieve accurate prediction of clinically significant prostate cancer and non-invasive risk stratification. Unnecessary prostate biopsy and overdiagnosis can be reduced to support the optimization of clinical diagnosis and treatment strategies.
Eligibility criteria
Qualifiers
Subjects who are scheduled to undergo or have undergone prostate biopsy or radical prostatectomy.
Subjects who have completed standard-of-care preoperative multiparametric MRI (mpMRI) and transrectal ultrasound (TRUS) examinations.
Subjects with complete pathological diagnosis results available.
Age between 40 and 90 years.
Disqualifiers
Prior history of pelvic radiation therapy or radical prostatectomy.
Incomplete or poor-quality mpMRI or TRUS images (e.g., motion artifacts, insufficient sequences).
Concurrent other primary malignant tumors.
Severe systemic diseases that may affect the evaluation of the prostate.
Trial design
Treatments tested in this trial
- No Intervention: Observational Cohort
Treatment groups
No treatment groups listed
Locations
1Liuzhou People's Hospital Affiliated to Guangxi Medical University545006, LiuzhouGuangxi, China
Sponsors and collaborators
Guangxi Medical University
Lead sponsor
Source ClinicalTrials.gov